Promega Enters into Agreement with GeneCopoeia
News Apr 23, 2008
Promega has entered into an agreement with GeneCopoeia to combine its HaloTag® protein fusion technology with GeneCopoeia’s extensive library of human and mouse open reading frame (ORF) OmicsLink™ sequences. The resulting OmicsLink ORF expression clones with HaloTag are ready for use, offering a potentially weeks of time savings to customers.
The large number of expression-ready ORF clones with HaloTag, combined with fluorescent or other ligands for HaloTag and optimized assay protocols, provide a complete solution broadly applicable to proteomics research, supporting both biochemical and cellular analysis of protein function.
“Our aim is to support scientists in their research, and this combined resource will enable them to easily incorporate these tools to improve protein function experiments,” explains Promega VP of Marketing Andy Bertera. “This collaboration with GeneCopoeia allows us to offer incredible breadth of prepared gene content to complement the multiple protein applications enabled by the HaloTag platform.”
“HaloTag complements our collections of genome-wide OmicsLink full length cDNA clones from human, mouse and other species," said Dr. Sun Lu, Executive Vice President of GeneCopoeia, Inc. GeneCopoeia’s 20,000 human and 15,000 mouse ORF clones were generated from sequence validated full length cDNA clones or high quality tissue cDNA libraries using the Company’s proprietary high-fidelity cloning technologies.
HaloTag is a multi-functional protein tag that binds covalently and specifically to a variety of synthetic ligands, and which enables tagged proteins to be labeled with fluorophores for both in vitro and in vivo imaging, or with immobilization agents (beads or other surfaces) for purification. Covalent and specific binding of a variety of synthetic reporter and immobilization ligands to HaloTag fusion proteins allow detection and or solid-phase fixation of tagged proteins.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.